Upon entry into the circulation, chylomicrons (containing apo B-48) produced by the small intestine, and VLDL (containing apo B-100) produced by the liver.

Slides:

Advertisements

Similar presentations

Eur Heart J 2013; 34:

Advertisements

European Heart Journal 2010; 31:

Cholesterol sources, biosynthesis and degradation  diet  only found in animal fat  biosynthesis  primarily synthesized in the liver from acetyl CoA.

Lipoproteins Clusters of lipids associated with proteins that serve as transport vehicles for lipids in the lymph and blood.

Cholesterol is among the lipids (fats) in the bloodstream. Source: Supplied from diet or synthesized by liver. Importance: 1.Form cell membranes and.

The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH by Antigone.

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:

1 Role of Triglycerides. 2 Objectives  Explain the metabolism of triglycerides and the relationship between triglycerides and HDL-C  Discuss the role.

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer.

Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction by Mortimer Korf-Klingebiel,

The combined influence of leisure-time physical activity and weekly alcohol intake on fatal ischaemic heart disease and all-cause mortality by Jane Østergaard.

L IPOPROTEINS. W HAT ARE LIPOPROTEINS ? Lipoproteins are molecules produced in the body and act as lipid transporters They consist of: Triglycerides Protein.

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:

Excessive heart rate increase during mild mental stress in preparation for exercise predicts sudden death in the general population by Xavier Jouven, Peter.

An update on regional variation in cardiovascular mortality within Europe by Jacqueline Müller-Nordhorn, Sylvia Binting, Stephanie Roll, and Stefan N.

Acute viral myocarditis by Robert Dennert, Harry J. Crijns, and Stephane Heymans EHJ Volume 29(17): August 25, 2008 Published on behalf of the.

Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis by Tuula A. Paajanen, Niku K.J. Oksala,

Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction †

Prognostic value of coronary artery calcium screening in asymptomatic smokers and non-smokers by Leslee J. Shaw, Paolo Raggi, Tracy Q. Callister, and Daniel.

Lab (6): Lipids profile KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab (Bioc 416) 2012 T.A Nouf Alshareef

Nordestgaard et al. EAS EFLM joint Consensus Panel. Eur Heart J 2016; online April 26.

Arginase I enhances vascular smooth muscle cell proliferation by increasing intracellular polyamine production (A and B) Arginase I enhances cell proliferation.

Figure 5 Recording of late potentials from multipolar catheter in infero-posterior scar (top panel) during sinus rhythm. The pivotal role of late potentials,

From: Global Banking: Recent Developments and Insights from Research*

Figure 1 Flow diagram displaying the proportions of patients with troponin measurements available from all eligible patients and the resulting study population.

Figure 1 Ischaemic endpoints

Figure 1 Study flow chart.

Fig. 1 Flow chart of study selection

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

Figure 2 The incidence of new onset AF, strokes, heart failure, and mortality according to the BMI (/ person-years). (Left: BMI

Figure 1 The flowchart depicts the total number of procedures in the Western Denmark Heart Registry (WDHR) and the exclusion of patients; NPR, National.

Figure 1 Prevalence of functional mitral regurgitation according to NYHA functional class (A; P

Figure 1 Relationship between creatine kinase-MB fraction elevation post-coronary artery bypass graft surgery with relative risk of mortality at 30 days.

Figure 1 Study flow chart

Classification of total cholesterol levels

Review of Cholesterol and Lipoproteins

II. assessment of dyslipidemias

Date of download: 2/22/2017 © The European Society of Cardiology All rights reserved. For permissions please

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Mechanism of mortality benefit associated with radial access

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 The major pathways of lipid metabolism

Figure 1 Sources of uncertainty introduced in each stage of the standard modelling approach for estimating ... Figure 1 Sources of uncertainty introduced.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Take home figure The protective role of CNP/NPR-B/NPRC.

Figure 1 Selection algorithm of patients being included in the German Aortic Valve Registry in 2014 and Figure 1 Selection algorithm of patients.

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Immunohistochemistry for human cell differentiation molecules in samples of the right ventricular septum from ... Figure 1 Immunohistochemistry.

Lipoprotein Metabolism

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Take home figure Proposed mechanisms of Staphylococcus aureus endocarditis. CVC, central venous catheter; IV, intravenous; S. ... Take home figure Proposed.

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Characteristics of included studies

Figure 1 Patient selection.

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 ABCDE of primary prevention.2

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Upon entry into the circulation, chylomicrons (containing apo B-48) produced by the small intestine, and VLDL (containing apo B-100) produced by the liver undergo LPL–mediated lipolysis mainly in peripheral tissues, notably adipose tissue and muscle. Chapman M J et al. Eur Heart J 2011;32: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

Metabolic pathways for HDL and triglyceride-rich lipoprotein remnants highlight their close interrelationship. Chapman M J et al. Eur Heart J 2011;32: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

Lipoprotein cholesterol as a function of increasing levels of non-fasting triglycerides in the general population. Chapman M J et al. Eur Heart J 2011;32: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

Chapman et al. EAS Consensus Panel. Eur Heart J 2011;32:

Hazard ratios for coronary heart disease and ischaemic stroke across quantiles of usual concentrations of triglycerides, HDL, and non-HDL cholesterol levels. Chapman M J et al. Eur Heart J 2011;32: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

Relationship of non-fasting triglycerides (up to and >5 mmol/L or 440 mg/dL) and risk of myocardial infarction, ischaemic stroke, and total mortality. Chapman M J et al. Eur Heart J 2011;32: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

Chapman et al. EAS Consensus Panel. Eur Heart J 2011;32:

Proposed algorithm for the management of high-risk individuals with elevated triglycerides and/or low HDL cholesterol at LDL cholesterol goal. aLDL-C at goal as recommended by the most recent European guidelines (2007);4 <2.5 mmol/L in high-risk patients, decreasing to <2.0 mmol/L in very high risk patients. Chapman M J et al. Eur Heart J 2011;32: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

Disclosures This work including Consensus Panel meetings were supported by unrestricted educational grants to the European Atherosclerosis Society from Merck, Kowa, Roche, and AstraZeneca. This funding also supported the Open Access publication charges for this article. These companies were not present at the Consensus Panel meetings, had no role in the design or content of the Consensus Statement, and had no right to approve or disapprove of the final document. Chapman et al. EAS Consensus Panel. Eur Heart J 2011;32: